Vol 52 No 11

Overall, 4 of 5 patients with low-grade disease who received bel-sar with light activation achieved a complete clinical response.

The target action date for the application is June 13, 2025.

"On-going innovation will continue to drive UTUC management forward, and with it will come on-going challenges of how to best study a relatively rare disease," write the authors.

"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.

The overall report rate per unit sold of the PEG hydrogel spacers was 0.40%.

Overall, a total of 693 patients received a PEG spacer in 2017 and 2510 received one in 2022, an increase of 262%.

“Pembrolizumab maintenance therapy after SABR boost to bladder tumor and concurrent radio-chemotherapy was well tolerated with promising efficacy in the early analysis," said Shang-bin Qin, MD.

Ga-68 PSMA-11 radiotracer may be a feasible option for SCINTIX radiation therapy in patients whose prostate cancer has spread to the bones.

Follow-up phase 3 analyses support a hypofractionated radiation therapy regimen to conventional dosing in patients with prostate cancer.

"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter.

“Our findings give patients and doctors valuable insights into what to expect after ADT treatment, helping them make informed decisions about managing side effects and improving long-term outcomes," says Amar U. Kishan, MD.

Andrea Necchi, MD, reported that pCR was 42% (95% CI, 28-56) in cohort 1 and 23% (95% CI, 10-41) in cohort 2.

Patients with at least 1 NE-positive marker were shown to have a worsened rPFS and OS.

According to the authors, “darolutamide significantly reduced the risk of radiological progression or death by 46%” (HR=0.54, 95% CI, 0.41-0.71, P < .0001).

“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD.

The results “support the prioritized development of TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer," said Michiel van der Heijden, MD, PhD.

Late-breaking data from ESMO 2024 suggest ipilimumab / nivolumab may be a new standard of care for non-clear cell renal cell cancer.